24 April 2018
By Dr Wendy Winnall - PCFA Research Team
Treatments for advanced and metastatic prostate cancer are rapidly evolving. Recent trials have shown that adding chemotherapy to androgen deprivation therapy leads to improved survival rates. But the length of time that a patient survives is not all that’s important to them. A new report has been published that examines the quality-of-life for men who start androgen deprivation therapy and chemotherapy at the same time.
To read the full article just log into the PCFA Online Community.
If you're not already a member, it is free and easy to join.
